18 March, 2025 | Online
17:00-18:00 CET
Chairs: Prof. Dr Alexander Möller (Zürich, Switzerland), Dr Susanne Vijverberg (Amsterdam, Netherlands)
Speakers: Dr Tom Ruffles (Hove, United Kingdom), Dr Elise Slob (Amsterdam, Netherlands)
Fees: Free for ERS members / €10 for non-members
Find out more about becoming a member
Participants in this webinar can benefit from translation during the live event. The translation function can be found underneath the live event's video player; up to 60 languages are available, with both subtitled and audio translation available. Please note that this is currently available for the live event only.
Learn more about this function.
Asthma is one of the most common chronic conditions in children, with significant variability in treatment response. Emerging research suggests that genetic variations influence how paediatric patients respond to asthma medications. This webinar will explore the current state of genotype-guided treatment for paediatric asthma, examining its potential to improve personalised therapy and patient outcomes.
One-hour webinar format: 45 minutes for presentations, followed by a 15-minute Q&A session.
Following this webinar, participants will be able to:
An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.
A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.
All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.
More information will be communicated in due course.